Eli Lilly and Company (LLY)
| Market Cap | 859.04B +23.3% |
| Revenue (ttm) | 72.25B +47.4% |
| Net Income | 25.28B +127.6% |
| EPS | 28.15 +129.1% |
| Shares Out | 891.74M |
| PE Ratio | 34.22 |
| Forward PE | 26.25 |
| Dividend | $6.92 (0.72%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 4,352,442 |
| Open | 948.95 |
| Previous Close | 934.60 |
| Day's Range | 943.80 - 984.45 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.48 |
| Analysts | Strong Buy |
| Price Target | 1,220.16 (+26.66%) |
| Earnings Date | Apr 30, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,220.16, which is an increase of 26.66% from the latest price.
News
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Lilly's obesity pill hits 5,612 prescriptions in third week after launch
Eli Lilly's newly launched oral weight loss drug was prescribed 5,612 times in the U.S. in the third week after its launch, according to analysts citing IQVIA data.
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the weight loss drug giant released better-than-expected first quarter 2026 earnings and raised fiscal 2026 guidance.
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.
Eli Lilly's stock is powering higher on fresh signs of booming demand for its weight-loss drugs. Will it be enough to drive a recovery for the stock?
Eli Lilly CEO on new GLP-1 pill: It's been out 20 days and we have over 20,000 patients
More than 20,000 people have started taking Eli Lilly's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday.
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
The Food and Drug Administration proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's blockbuster obesity and diabetes medications from the list of drugs that outsourcing fa...
QCOM Rally, RCL Regains Bookings Pace, LLY Soars
While Mag 7 names take a lot of the headlines after earnings, the moves from Qualcomm (QCOM), Royal Caribbean (RCL) and Eli Lilly (LLY) are on Diane King Hall's radar following Thursday's open. She br...
Eli Lilly and Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% revenue growth, strong launches (notably Foundayo), and robust pipeline progress, with full-year guidance raised to $82–$85 billion. Key products and international expansion drove results, while new access programs and acquisitions support future growth.
US FDA proposes excluding weight-loss drugs from compounding list
The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk and Eli Lilly's weight-loss drugs on the list of drugs outsourcing facilities can use for c...
More than 20,000 people are taking Eli Lilly's weight loss pill, CEO says
More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo in the first few weeks after its launch, CEO Dave Ricks said. The FDA approved Lilly's once-daily pill Foundayo earlier this mo...
Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pills
Consumer demand for blockbusters Mounjaro and Zepbound helped offset declining prices for the drugs.
Eli Lilly stock jumps 6% after strong earnings and raised guidance
Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its...
Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket
Revenue tied to Lilly's Zepbound and Mounjaro more than doubles from the same period last year.
Lilly's stock rallies as sales of GLP-1 drugs nearly double
Eli Lilly's GLP-1 franchise brought in a total of $12.9 billion in sales in the first quarter as demand continued to soar for the drugs commonly used for weight loss.
Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
Eli Lilly raised its annual profit forecast and posted better-than-expected first quarter on Thursday, on steady demand for its weight-loss and diabetes drugs Zepbound and Mounjaro, in its first res...
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound. Q1 2026 EPS increased by 170% to $8.26 on a r...
Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expects
Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the healthcare sector. The company's newly approved GLP-1 pill for o...
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Eli Lilly and Company (NYSE:LLY) will release earnings for its first quarter before the opening bell on Thursday, April 30.
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings
Eli Lilly is scheduled to report its latest quarterly earnings ahead of the opening bell Thursday, with shares seen potentially falling to their lowest level in months following the report.
Eli Lilly investors are eager for Foundayo insight after early launch data
Eli Lilly investors will be searching for something they won't find in any first-quarter financial figures reported on Thursday: insight into the launch of weight-loss pill Foundayo.
Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion
AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S. drugmaker Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic ...
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Boehringer Ingelheim said on Tuesday its experimental obesity drug led to average weight loss of up to 16.6% in a late-stage trial, as the unlisted German drugmaker seeks to catch up with obesity dr...
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst
Eli Lilly's Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth.
Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio.